id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10174 R37224 |
Blotière (Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Craniosynostosis | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
16.46 [0.79;343.08] C excluded (control group) |
2/913 0/2,997 | 2 | 913 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10051 R36498 |
Blotière (Valproate) (Controls unexposed NOS) (Mixed indications), 2019 | Craniosynostosis | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 5.50 [0.70;20.00] | 2/913 766/1,875,733 | 768 | 913 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9297 R32309 |
D'Souza (Valproate) (Controls unexposed, disease free), 1991 | Cranyosynostosis (saggital suture) | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
123.00 [1.00;15058.31] C excluded (control group) |
0/1 0/62 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9298 R32338 |
D'Souza (Valproate) (Controls unexposed, sick), 1991 | Cranyosynostosis (saggital suture) | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 15.00 [0.12;1923.88] C | 0/1 0/8 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 6.12 [1.26;29.85] | 768 | 914 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate) (Controls unexposed NOS) (Mixed indications; 2: Valproate) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9297, 10174